Researchers at the University of Cambridge have developed a monoclonal antibody drug that could help combat antimicrobial-resistant bacterial infections, specifically targeting Acinetobacter baumannii, a hospital-acquired infection common in Asia. Using genetically engineered mice with human-like immune systems, they produced nearly 300 antibodies and identified one, mAb1416, as the most effective at preventing infection. This antibody significantly reduced bacterial load in treated mice. Since A. baumannii is resistant to nearly all antibiotics, especially in hospitals, this breakthrough offers a promising new treatment. Further research is needed to refine the drug and conduct safety trials. The study was published in Nature Communications.
4 Likes
i didnt know antimicrobial resistance is such a huge issue!
2 Likes
Thank you for sharing this breakthrough! Monoclonal antibodies like mAb1416 could be a game-changer in the fight against antimicrobial resistance, especially for hospital-acquired infections like Acinetobacter baumannii, which is notoriously hard to treat. It’s amazing that researchers could leverage genetically engineered mice to identify such an effective antibody—this approach could pave the way for new treatments beyond traditional antibiotics.
1 Like
what cant monoclonal antibodies do omg!!
1 Like